Each year, the Home Office publishes statistics relating to regulated scientific procedures that are carried out on protected living animals in Great Britain. The reports give statistics on experimental procedures carried out on animals as well as on the creation and breeding of genetically altered animals. The report also covers what types of animals are used, and what quantities of each are used.
What might a no-deal Brexit mean for pharmaceutical companies in the UK? What might it mean for patients and businesses? BIA CEO spoke to BBC Newsnight's Helen Thomas about the implications of Brexit on our sector. Two BIA members also features; AstraZeneca and Quay.
Parliament has voted in favour of amendment NC17 to the Trade Bill that will make it a negotiating objective for the UK Government to seek the UK's participation in the European medicines regulatory network.
A big thank you to all of the BIA members who joined our 18th annual Parliament Day last Thursday. Despite the event falling in what has been a tumultuous week for Westminster, it proved a roaring success.
The day was most enjoyable and effective and had the added twist of the government releasing their White Paper on Brexit in the middle of it. The paper was largely positive for our sector, with significant detail on a proposed future relationship on medicine regulation, aligning with the key points we have been consistently advocating for two years. In terms of science and innovation and R&D funding, the UK proposes a “science and innovation accord” which will provide for UK participation in EU research funding programmes.
Cancer Research UK and MedImmune have teamed up and formed a lab which is focused on studying oncology, and improving the science of fighting cancer. Scientists from CRUK and MedImmune work alongside eachother in the CMAL lab, with the aim of taking one of the projects to the status of nominated agent in a clinic within five years of work in the lab.
NovaBiotics, the clinical stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases, this morning announces its oral therapy for cystic fibrosis, Lynovex®, has met the study objectives of the CARE CF 1 clinical trial.
What a week we’ve picked for our annual parliament day this Thursday. Chief Executives and senior management from over 40 of our members will join us on the day to interact directly with over 30 ministers, MPs and senior civil servants, raising the profile of the biotech sector. It’s now the day that the government releases its white paper on the UK’s future relationship with the EU post Brexit.
Oxford, UK, July 5 2018 - The state-of-the-art Schrödinger Building at The Oxford Science Park, one of the UK's leading parks for science and technology companies, is to be opened this afternoon by Sam Gyimah MP, Minister of State for Universities, Science, Research & Innovation.